Member Info for RayPointer

Are you bored Ruck?

😀

PM

You say:

"Well I have information that indicates it is not the case.

The deal is very much on."

Are you going to share with us this information?

Puffing Billy took me to London when I made my first investment in Scancell

Let's have more of a bullet train from now on.

Welcome back c7.

Good afternoon Bushy.

No posts over the weekend!

You didn't get laid by any chance?

The other explanation for the SP drop is that folk realised that the supposed merger of EUDA and THX was not happening , and they just lost confidence, which is hardly surprising.

Hi Chester

My take on this is that the market size for late stage unresected melanoma is $1.5 per annum currently.

Scancell's plan is to prove iSCIB1+ with the 2 CPIs and then this becomes the marketable product for unresected late stage melanoma in combination with CPIs.

However, if and when a deal is made, our partner must surely be mindful of SCIB1's monotherapy success for resected late stage melanoma in the original trial. The chances are they would want to conduct a trial with iSCIB1+ both as a monotherapy and also with CPIs for late stage resected melanoma. So that trial, if it takes place, and it is at least as successful as the original trial, would open up a second market for resected late stage melanoma.

But it may not end there, since iSCIB1+ may also be effective as a monotherapy in early stage melanona. Richard Goodfellow did state that SCIB1 was vey good at mopping up melanoma metastases. This suggests that maybe it could also be used at any stage, especially if iSCIB1+ proves to have the same lack of toxicity as SCIB1.

I wouldn't like to guess what percentage of the total melanoma market iSCIB1+ would attract.

https://www.databridgemarketresearch.com/reports/global-malignant-melanoma-treatment-market

This article suggests that the market size is expanding rapidly, possibly as a result of global warming and depletion of the ozone layer.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960955/

Thank you Cleaner.

https://www.scancell.co.uk/Data/Sites/1/media/docspres/agm-presentationnovember-2022_final.pdf

See Slide 19

That famous swim chart shows superior results with SCIB1 alone (no CPI included) in the adjuvant setting, albeit with only 16 patients.

I'm tempted to say far superior results since 14 of the 16 patients were still alive after 5 years (12.5% death rate) whereas the Moderna trial death rate was 22% after 2 years.

Again, caution because of low numbers in the SCIB1 trial.

However, overall I would be tempted to say "try again Moderna"

Much better to steal the stock

https://www.youtube.com/watch?v=yWnP-UdWabs

This sentence in the RNS is music to my ears:

"Recruitment into the iSCIB1+ cohort is expected to be complete by the end of Q2 2024, with early data expected in Q3 2024."

I should think that many patients that have been turned away from the current Scope trial are now eligible for the new cohort.

Of course, iSCIB1+ now has to prove itself.

Yes, the muted reaction of the market certainly gives us happy clappers more opportunities to increase our holdings in SCLP.

To me, this is an very important RNS since it represents another essential hurdle overcome.

And the best to you also C7.

Hope to see you posting more frequently here.

Hello C7.

How are you doing, fella?

The market still fails to comprehend the importance on this trial.

Leon Coetzer alias King Midas 😂

Must be another typo from BT. 😂

Big pharma have read statistics textbooks and are looking for data on at least 30 patients.

This was mentioned at the AGM. I don't think Lindy would consider a deal until that number is reached on the iScib1+ cohort. That's unless she is made an offer she can't refuse.

Do the maths again Bushy. The 13,000 tones is an annual figure.

"Meanwhile, I start flying.."

Nice one Porky

"We know the reasons why TRX were picked as it has been discussed 100s of times."

Did Val pick TRX or, in reality, were they the only organisation that showed any interest in 201?